WATERTOWN, Mass.--(BUSINESS WIRE)--BioSensics LLC, a leader in developing wearable sensor technologies for clinical research and medical applications, has received a grant award from the National Institutes of Health (NIH) to develop technology for continuous, remote monitoring of cognitive decline. This technology will enable objective assessment of instrumental activities of daily living, life space, and also digital social interactions, which are biomarkers of many diseases and disorders from Alzheimer’s disease and dementia to depression. With the addition of this new technology, BioSensics seeks to expand the capabilities of its Sensor-Integrated Digital Platform for Clinical Trials to include tools for objective measurement of cognitive and mental health.
Dr. Joseph Gwin, Vice President of Research and Development at BioSensics, announced this NIH grant award yesterday during his presentation at DPharm: Disruptive Innovations to Advance Clinical Trials in Boston, MA, where Dr. Gwin discussed the critical role that wearable sensors can play in clinical trials. “BioSensics offers a wide range of solutions and services to measure movement and mobility related endpoints in clinical trials. We are thrilled to have the support of the NIH to further expand our offerings to measure endpoints that are directly relevant to a wide range of mental and cognitive disorders,” said Dr. Gwin.
The 3-year project will be conducted in collaboration with Baylor College of Medicine. The solution, which consists of a wearable movement sensor, GPS, and software for measuring digital social interactions, will have impacts in both clinical trials and clinical practice. “Technology can play a key role in promoting healthy and independent aging. The ability to continuously monitor cognitive health plays a key role in managing care and support for the elderly population,” said Dr. Bijan Najafi, professor in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, who is the Principal Investigator of the new grant award.
In May 2018, BioSensics announced the launch of its Sensor-Integrated Digital Platform for clinical trials. This platform was also developed in part with funding from the NIH and is currently being used in clinical trials for a variety of indications including neurodegenerative diseases, stroke, and cognitive disorders. “We have been very pleased with the favorable reception of our platform by the pharmaceutical industry and look forward to steady growth of our clinical trials division,” said Dr. Gwin.
Learn more at www.biosensics.com/solutions/clinical-trials
BioSensics is a globally recognized provider of wearable sensor technologies for clinical research and medical applications. BioSensics technologies include innovative solutions for aging-in-place, telehealth, chronic disease management, physical therapy, rehabilitation, fall risk assessment, and clinical research and trials.